Radius To Present At The Cowen and Company 35th Annual Health Care Conference

WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 35th Annual Health Care Conference on March 3, 2015 at 9:20 a.m. EST at the Boston Marriott Copley Place, Boston, Mass.

The Company’s presentation will be webcast live on the Company’s website at www.radiuspharm.com, and a replay of the presentation will be available on the Company’s website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company’s lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.

CONTACT: Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 bryan@radiuspharm.com
Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC